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PI3K activity determines positive and negative selec-
tionofBcells, akeyprocess for immune toleranceand
B cell maturation. Activation of PI3K is balanced by
phosphatase and tensin homolog (Pten), the PI3K’s
main antagonistic phosphatase. Yet, the extent of
feedback regulation between PI3K activity and
Pten expression during B cell development is un-
clear. Here, we show that PI3K control of this pro-
cess is achieved post-transcriptionally by an axis
composed of a transcription factor (c-Myc), a micro-
RNA (miR17-92), and Pten. Enhancing activation of
this axis through overexpression of miR17-92 re-
constitutes the impaired PI3K activity for positive
selection in CD19-deficient B cells and restores
most of the B cell developmental impairments that
are evident in CD19-deficient mice. Using a genetic
approach of deletion and complementation, we
show that the c-Myc/miR17-92/Pten axis critically
controls PI3K activity and the sensitivity of immature
B cells to negative selection imposed by activation-
induced cell death.
INTRODUCTION
Fate decisions of developing B cells critically depend on sig-
nals that are generated by the B cell antigen receptor (BCR).
Immature and transitional B cells encountering self-antigens
undergo negative selection by receptor editing or are eliminated
by apoptosis (clonal deletion), whereas appropriate ligand-inde-
pendent basal signals are thought to promote development and
maturation of cells expressing innocuous receptors in a process
referred to as positive selection (Monroe, 2006; Rowland et al.,
2013). BCR-mediated negative selection has been demon-
strated in mutant and normal mice and was found to depend
on developmental stage or site of self-antigen encounter (Edry
andMelamed, 2004; Monroe, 2006; von Boehmer andMelchers,
2010). The deletion of these cells is facilitated by a mechanismThis is an open access article under the CC BY-Ncalled activation-induced cell death (AICD) (Donjerkovic and
Scott, 2000; Eeva and Pelkonen, 2004). Impaired positive selec-
tion has been shown in mice deficient in BCR signaling regu-
latory co-receptors such as CD45 and CD19, as reflected by a
significant reduction in numbers of B cell in the periphery (Cyster
et al., 1996; Rickert et al., 1995). Crossing of CD45-and-CD19-
deficient mice with immunoglobulin transgenic mice to express
an innocuous BCR suggests that this positive selection is medi-
ated by ligand-independent signals (Cyster et al., 1996; Shivtiel
et al., 2002). Inappropriate basal signals impose a develop-
mental block of immature B cells and ongoing rearrangements
(Diamant et al., 2005; Shivtiel et al., 2002; Verkoczy et al.,
2007). However, whereas in mature B cells the dependence on
tonic BCR activity for survival has been demonstrated (Sriniva-
san et al., 2009), the nature of ligand-independent signals for
B cell positive selection is not completely understood.
The phosphoinositide 3-kinase (PI3K) pathway has emerged as
a critical determinant for B cell development and survival (Herzog
et al., 2008; Okkenhaug and Vanhaesebroeck, 2003; Srinivasan
et al., 2009;Werner et al., 2010) andhasbeen found tobe involved
in bothpositive (Diamant et al., 2005;Monroe, 2006; Shivtiel et al.,
2002; Tze et al., 2005; Verkoczy et al., 2007) and negative (Cheng
et al., 2009; Clayton et al., 2002; Pogue et al., 2000) selection.
CD19 is the main contributor for PI3K activity in B lineage cells
as it directly associates with PI3K upon phosphorylation by Src-
family kinases (Tuveson et al., 1993). Inappropriate PI3K activity
isoften associatedwithpathologicalmanifestationswith impaired
signaling leading to immunodeficiency, whereas unrestrained
signaling promotes autoimmunity and leukemia (reviewed in
Okkenhaug and Vanhaesebroeck, 2003). This paradigm is best
exemplified inmicewhereCD19expression isaltered:CD19-defi-
cient mice have severe defects in B cell development, activation,
anddifferentiation (Diamant et al., 2005; Engel et al., 1995; Rickert
et al., 1995; Shivtiel et al., 2002), whereas mice transgenic for
human CD19 develop autoimmunity (Engel et al., 1995). More
recently, CD19 was found to be a major BCR-independent regu-
lator of c-Myc levels in B cell neoplasms by activating the PI3K/
Akt/GSK3 axis to promote B cell transformation and lymphoma
progression (Chung et al., 2012; Poe et al., 2012). Hence, appro-
priate tuning of PI3K activity is critical for life and death decisions
during positive and negative selection of B cells.Cell Reports 16, 419–431, July 12, 2016 ª 2016 The Authors. 419
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Whereas CD19 is the major activator of PI3K in B lineage cells,
the phosphatase and tensin homolog (Pten) has the major role of
balancing PI3K activity by converting PIP3 to PIP2 (Suzuki et al.,
2008). Pten is expressed in B lineage cells and has been shown
to play a role in B cell differentiation (Alkhatib et al., 2012; Anze-
lon et al., 2003; Suzuki et al., 2003). Moreover, Pten heterozy-
gosity is sufficient to result in significantly enhanced PI3K activity
(Suzuki et al., 1998), and ablating both Pten alleles reconstitutes
B1 and marginal zone (MZ) B cell development in CD19/
(CD19KO) mice (Anzelon et al., 2003). However, the extent of
feedback regulation between PI3K signaling and Pten expres-
sion during B cell development is unclear. Several studies have
shown that some PI3K components inhibit Pten function (re-
viewed in Carracedo and Pandolfi, 2008) and provided sugges-
tive evidence for the existence of such a reciprocal regulatory
mechanism. More recently, a genomic screening of Burkitt’s
lymphoma cells suggested that the overexpression of c-Myc,
which is the defining oncogene of this cancer, and its target
microRNA17HG inhibit Pten and augment PI3K activity, resulting
in increased tumorogenicity (Schmitz et al., 2012). However, the
relevance of this to normal cells, where the expression of c-Myc
and its target genes is tightly regulated, is unclear.
Here, we explored the role of microRNAs (miRNAs) as po-
tential mediators by which the PI3K pathway controls Pten
expression in developing B cells. Using CD19KO mice that
conditionally overexpress miR17-92 in the B lineage, we show
an axis composed of a transcription factor (c-Myc), a miRNA
cluster (miR17-92) and a signaling molecule (Pten), which is
directly activated by PI3K to physiologically control expression
of Pten during B cell development. We found that the c-Myc/
miR17-92/Pten axis is critical for balancing PI3K activity in its
control of B cell-fate decisions for positive and negative selec-
tion. Furthermore, we found that overexpression of miR17-92
effectively compensated for the impaired PI3K activity in
CD19-deficient B cells thereby reconstituting the majority of
B cell developmental impairments that are evident in CD19KO
mice.
RESULTS
Ablation of Dicer Impairs PI3K Signaling and Stimulates
Apoptosis of Transitional B Cell, Whereas Pten
Heterozygosity Restores PI3K Activity to Promote
Survival
PI3K activity is necessary to promote positive selection of imma-
ture and transitional B cells (Diamant et al., 2005; Monroe, 2006;
Shivtiel et al., 2002; Tze et al., 2005; Verkoczy et al., 2007). Since
miRNAs have been shown in a variety of systems to be critical
regulators of developmental checkpoints, we studied whether
microRNAs regulate life and death decisions at this develop-
mental checkpoint. To address this globally, we decided to
establish an inducible system to generate Dicer-ablated transi-
tional B cells in vivo, since conditional deletion of Dicer in proB
cells blocks Pro-to-preB cell development and stimulates preB
cell apoptosis (Koralov et al., 2008). In these experiments, we
used mice transgenic for human CD20 (hCD20), where B cells
are eliminated upon administration of mouse anti-human CD20
antibodies (Ahuja et al., 2007), to set up a depletion-autorecon-420 Cell Reports 16, 419–431, July 12, 2016stitution mouse model where most of the splenic B cells are
at the transitional stage (Figure S1). We crossed these strains
to generate hCD20Tg/Mx-cre/Dicerfl/fl mice, where we induced
ablation of Dicer in transitional B cells upon administration of
poly(I)(C). Deletion of Dicer in B cells upon this treatment was
confirmed by the absence of miRNAs (Figure S2). We found
that the dicer ablated mice had a dramatic loss of >70% of tran-
sitional B cells in the spleen (from 26% in hCD20 to 7% in
hCD20Tg/Mx-cre/Dicerfl/fl mice; Figures 1A and 1C), and An-
nexin V staining revealed that this loss is caused by apoptosis
(Figures 1B and 1C). Intracellular flow cytometry analysis re-
vealed that in Dicer-ablated transitional B cells PI3K activity is
impaired, as reflected by the profoundly reduced level of Akt
phosphorylation (Figure 1D; MFI = 585 relative to control MFI =
707). Hence, we concluded that the global reduction in miRNAs
impairs PI3K signaling in transitional B cells and stimulates
apoptosis of these cells.
Next, we tested how the global reduction of miRNAs can sup-
press PI3K activity. One possible mechanism by which this sup-
pression may be achieved is through enhanced expression of
the tumor suppressor Pten. Indeed, analysis of splenic B cells
from Dicer-ablated mice revealed that expression of Pten is
significantly elevated (Figure 1E). To confirm the physiological
relevance of this mechanism, we tested whether reducing
expression of Pten can reconstitute PI3K activity to rescue
Dicer-ablated transitional B cells. We decided to use an induc-
ible genetic approach by ablating only one Pten allele in mice,
since Pten heterozygosity is sufficient to result in significantly
enhanced PI3K activity (Suzuki et al., 1998). To achieve this,
we generated hCD20Tg/Mx-cre/Dicerfl/fl/Ptenfl/+ mice and co-
ablated both Dicer alleles and one of the Pten alleles in transi-
tional cells. This experimental maneuver effectively reconstituted
tonic PI3K activity (measured by Akt phosphorylation; Figure 1D;
MFI = 901 relative to control MFI = 707 and Dicer ablated MFI =
585) and promoted survival of transitional B cells (revealed by to-
tal B cells numbers and %Annexin V staining; Figures 1A–1C).
Hence, we concluded that a regulatory network exists between
PI3K and Pten whose role is to tune PI3K activity for positive se-
lection, and that this network is mediated post-transcriptionally
bymiRNAs. In the next set of experiments, we attempted to iden-
tify this network.
The c-Myc/miR17-92/Pten Axis Regulates Pten
Expression to Balance PI3K Activity in B Lineage Cells
A major mechanism by which PI3K promotes survival is by
increasing the expression of c-Myc transcription factor (Sears,
2004). Thus, we next tested whether c-Myc regulates the
expression of Pten, to enhance PI3K activity and to promote
survival, in a miRNA-mediated mechanism. One possible mech-
anism by which c-Myc can exert this regulation is via miR17-92,
as the miR17-92 locus is a direct target of c-Myc (O’Donnell
et al., 2005), and the miR17-92 cluster negatively controls
expression of Pten (Xiao et al., 2008). Hence, we hypothesized
that a c-Myc/miR17-92/Pten autostimulatory loop exists and
enhances activation of the PI3K pathway. Accordingly (as
illustrated in Figure 2A), a PI3K-mediated increase in c-Myc stim-
ulates expression of miR17-92, should, in turn, lead to degrada-
tion of Pten mRNA (and perhaps inhibition of Pten translation),
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Figure 1. Ablation of One Pten Allele Promotes Survival of Dicer-Deleted Transitional B Cells
Mice with the indicated genotypes were injected with mouse anti-hCD20 to deplete B cells (depletion-autoreconstitution model for generation of transitional B
cells in the spleen, see Supplemental Information). On days 7, 10, and 13, mice were injected with poly (I)(C) (400 mg/mouse/injection), and splenic B cells were
analyzed on day 21.
(A) Time scheme of the experiment (top), and a representative fluorescence-activated cell sorting (FACS) analysis of percentage of B cells among total sple-
nocytes (B220+, bottom).
(B) Annexin V staining of splenic B cells (gated on B220+).
(C) Graphs depict total cell numbers of splenic B cells shown in (A) (top) and percentage of annexin V+ B cells shown in (B) (bottom) for individual mice and group
mean (n = 4). Significance shown is *p < 0.05; **p < 0.001.
(D) Flow cytometry analysis for baseline pAkt (S473, gated on B220+ splenic cells).
(E) Splenic B cells from control and Dicer-ablated mice [treated with poly(I)(C)] were lysed and expression of the indicated proteins was determined by western
blotting. Shown are representative results for two control and three Dicer-ablated mice (from n = 4 for each group).thus increasing activation of the PI3K pathway. Indeed, these
regulatory connections were supported by a Gene Set Enrich-
ment Analysis (GSEA) which highlighted the enrichment (i.e.,
change in rank) of shared Myc miR-17-92 and mirR-17-92 only
targets between gene expression profiles of CD19 high and
low B cells (Figure 2B, top and bottom panels, respectively;
see Supplemental Experimental Procedures; NES = 1.47, p <
0.02, and NES = 1.35, p < 0.07 for shared miR-172 and Myc
and miR-172 only targets, respectively).
To validate the relevance of a potential c-Myc/miR17-92/Pten
loop in B cells, we used splenic B cells from CD19KO mice,
where activation of the PI3K pathway is impaired (Buhl et al.,
1997; Otero et al., 2001) (see also Figure S5). Consequential to
the dampened PI3K activity, expression of c-Myc in CD19KO
B cells is significantly reduced relative to wild-type (WT) B cells
(Figure 2C; Chung et al., 2012). In agreement with our hypothesis
and the low levels of c-Myc, we found in CD19KO B cells signif-
icantly reduced expression of miR19b (miRNA of the miR17-92
cluster that binds to the 30 UTR of Pten [Xiao et al., 2008]),
whereas Pten mRNA and protein expression were significantly
increased, relative to WT B cells (Figures 2C and 2D).
To link the altered miR19b and Pten expression in CD19KO
B cells to the reduced expression of c-Myc in these cells, we
used GSK3 inhibitors that prevent degradation of c-Myc. We
found that elevating c-Myc in CD19KO B cells (Figure 2C, rightlane) increased the expression of miR19b and repressed the
expression of Pten protein and mRNA to levels not different
than those found in WT B cells (Figures 2C and 2D). To confirm
these findings, we performed the reciprocal experiment where
we treated WT B cells with anti-sense c-Myc oligonucleotides
to reduce its expression (Leider and Melamed, 2003) (see also
Figure S7). As shown in Figure 2E, this resulted in a significantly
reduced expression of miR19b and increased levels of Pten.
Hence, we concluded that an autostimulatory axis containing
the transcription factor c-Myc, miR17-92, and the signaling
molecule Pten regulates the PI3K pathway and that this loop is
impaired in CD19KO B cells (Figure 2E).
Overexpression of miR17-92 Restores PI3K Signaling
and Partially Rescues B Cell Development and Positive
Selection in CD19KO Mice
Since PI3K signaling is critical for B cell development (Clayton
et al., 2002), our findings suggested an important role of the
c-Myc/miR17-92/Pten axis in the regulation of this process.
This hypothesis was supported by an earlier study showing
that ablation of Pten rescues development of B1 and marginal
zone (MZ) B cells in CD19KO mice (Anzelon et al., 2003), where
PI3K activation and positive selection are impaired (Diamant
et al., 2005). Based on this and our results, we postulated that
overexpression of miR17-92 would reconstitute PI3K activity toCell Reports 16, 419–431, July 12, 2016 421
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Figure 2. The c-Myc/miR17-92/Pten Axis
Regulates Pten Expression to Balance PI3K
in B Lineage Cells
(A) A scheme showing the proposed function of the
c-Myc/miR17-92/Pten axis (highlighted in red) in
controlling PI3K activity and the consequential cell-
fate decision for positive and negative selection.
(B) miR-172 and Myc target genes are differentially
expressed between CD19 high and low B cells pro-
fileGene Set Enrichment Analysis of shared targets
ofMyc andmiR-172 (top) andmiR-172only (bottom)
between CD19 high and low B cells profiled by mi-
croarray (false discovery rate [FDR] <0.1, p values
and normalized enrichment scores of 1.47, p < 0.02,
and 1.35, p < 0.07, respectively). The transcriptome
profile is indicated by the red-blue bar at the bottom
of each plot, running from CD19 high to low. Vertical
black lines, the distribution of the gene set within this
profile; green, the enrichment profile.
(C and D) Splenic B cells fromWT or CD19KOmice
were cultured for 6 hr in the presence or absence of
GSK3 inhibitor Bio-acetoxime, lyzed, and analyzed
by western blotting for the indicated proteins (C) or
by qPCR for expression of Pten mRNA and mature
miR19b (D). Pten and c-Myc bands detected by
western blots were quantified and normalized to
their respective actin bands, and fold change for
CD19KO and CD19KO+GSK3inh was calculated
relative to control (CD19+/+) cells. Shown in (C) are
representative results and summary of three ex-
periments (mean ± SEM) (*p < 0.05 from control).
(E) Splenic B cells from WT mice were cultured for
16 hr in the presence or absence of antisense
c-Myc oligonucleotides, lysed. and analyzed by
qPCR for expression of Pten mRNA and mature
miR19b. Results shown are mean ± SE of three
experiments.rescue B cell development in CD19KOmice by inhibiting expres-
sion of Pten. To test this, we generated mice deficient of CD19
(homozygous for CD19-cre [Rickert et al., 1995]) that are also ho-
mozygous for a miR17-92 transgenic allele, which was inserted
into the Rosa26 locus and is conditionally turned on by cre-medi-
ated recombination in B cells (CD19KO miR17-92Tg/Tg) (Xiao
et al., 2008). To assess whether PI3K signaling is restored during
B cell development, we generated interleukin-7 (IL-7)-driven BM
cultures from control, CD19KO, and CD19KO miR17-92Tg/Tg
mice. Phospho-flow analysis revealed that upon BCR stimula-
tion the impaired Akt phosphorylation that was evident in imma-
ture immunoglobulin M+ (IgM+) CD19KO B cells was restored in
CD19KO miR17-92Tg/Tg immature B cells (Figures 3A and 3B).
Further, Pten expression, which was high in CD19KO B cells,
was repressed and c-Myc expression, which was suppressed
in CD19KO B cells, was enhanced in CD19KO miR17-92Tg/Tg
B cells (Figure 3C). This suggests that overexpression of
miR17-92 restored PI3K activity in developing B cells deficient
of CD19 via negative regulation of Pten expression.
Next, to address whether restoration of PI3K activity in
CD19-deficient cells by overexpression of miR17-92 can rescue
B cell development and positive selection in CD19KO mice, we
analyzed peripheral B cell populations in control, CD19KO, and
CD19KO miR17-92Tg/Tg mice. The results, summarized in Fig-422 Cell Reports 16, 419–431, July 12, 2016ure 4, showed that the majority of the impairments in B cell
development that were readily observed in CD19KO mice were
rescued by overexpression of miR17-92. We found that spleen
cell cellularity in CD19KO miR17-92Tg/Tg mice, as measured
by spleen cell size and total cell numbers (Figures 4B and 4D)
and percentages of total splenic B cells (B220+; Figure 4A)
were completely restored to normal levels. Further analysis for
specific B cell subsets in the spleen revealed that sizes of
the mature B2, follicular (FO), and transitional B cells that are
severely reduced in CD19KOmice were restored to normal sizes
in CD19KOmiR17-92Tg/Tgmice (Figures 4C and 4D). Moreover,
in the peritoneal cavity the B1a cell subset, which was nearly
completely absent in CD19KO mice (Rickert et al., 1995), was
partially restored in CD19KO miR17-92Tg/Tg mice (Figure 4E).
Interestingly, in CD19KO mice expressing one copy of the
miR17-92 transgene we observed an intermediate phenotype
of partial restoration for each of these B cell subsets (Figures
4D and S3), suggesting that miR17-92 dosage is critical to fully
supplement PI3K activity in CD19KO mice. However, develop-
ment of the marginal zone (MZ) B cell subset was not rescued
in CD19KO miR17-92Tg/Tg mice as compared to CD19KO (Fig-
ures 4C and 4D). Last, B cell responsiveness was also not
rescued in CD19KO miR17-92Tg/Tg mice as evidenced by
lack of germinal center B cells in the spleen upon sheep red
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Figure 3. Overexpression of miR17-92 Reconstitutes PI3K Activity in CD19KO Immature B Cells
IL-7-driven BM cultures were prepared from mice of the indicated genotypes.
(A) Cells grown in cultures were stimulated with fluorescently labeled anti-IgM antibodies for 5 and 10 min, fixed, and subsequently stained intracellular for pAkt.
Flow cytometry analysis for pAkt gated on immature B cells that were revealed by IgM fluorescence.
(B) Summary of increment in pAkt after 5 min of stimulation calculated as (MFI pAkt stimulation – MFI pAkt unstimulated)/MFI pAkt unstimulated (*p < 0.05).
(C) Cells grown in cultures were lysed and analyzed for the indicated proteins by western blotting. Shown are representative results from individual mice (n = 3 in
each group).blood cell (SRBC) priming and complete absence of IgG1 in
serum (Figures 4F and 4G), whereas other antibody isotypes
were detected (Figure S3). These results indicate that enhancing
PI3K activity by overexpression of miR17-92 rescues B cell
developmental impairments that are imposed by CD19 defi-
ciency but not B cell activation defects.
The c-Myc/miR17-92/Pten Loop Regulates AICD in B
Lineage Cells
Antigen receptor signaling is required not only for developmental
progression of B cells but also to eliminate self-reactivity. Liga-
tion of the BCR by autoantigens induces AICD in immature
B cells (Edry and Melamed, 2004; Monroe, 2006; Nemazee,
2000), a process that is regulated mainly by the PI3K pathway
(Cheng et al., 2009; Clayton et al., 2002; Pogue et al., 2000). In
agreement with these results, we showed that immature B cells
deficient of CD19, mount increased sensitivity to BCR-induced
AICD relative to control cells (about 1.5-fold; Figure 5A). Based
on these results, we postulated that the c-Myc/miR17-92/Pten
axis, which we showed to balance the PI3K pathway, may also
function to tune the threshold to AICD in immature B cells.
To test this mechanistically, we used the immature B lym-
phoma cell line WEHI-231, previously shown to undergo AICD
in response to BCR ligation and used asmodel for B cell negative
selection (Benhamou et al., 1994; Hasbold and Klaus, 1990).
Knockdown (kd) of CD19 in these cells effectively suppressed
the PI3K pathway as revealed by altered phosphorylation of
Akt, GSK3, and reduced expression of c-Myc in response to
BCR ligation (Figure S4). We found that suppression of PI3K
in CD19kd cells reduces activity of the c-Myc/miR17-92/Ptenaxis, as indicated by reduced expression of miR19b (Figure 5B)
and increased expression of Pten mRNA and protein (Figures 5B
and 5C) in CD19kd cells relative to CD19wt cells.
Moreover, the impaired PI3K activity in CD19kd cells resulted
in a heightened sensitivity to AICD, as revealed by a 2-fold in-
crease in apoptosis relative to CD19wt cells (Figure 5D). To sup-
port the role of the c-Myc/miR17-92/Pten axis in mediating the
increased AICD in CD19kd cells, we show that a GSK3 inhibitor
effectively rescued both CD19kd and CD19wt WEHI cells from
AICD as revealed by a 50% reduction in apoptosis (Figure 5D).
Moreover, suppression of Pten expression upon infection with
a vector encoding Pten-specific short hairpin RNA (shRNA)
(shPten [Fellmann et al., 2013]) rescued from AICD, whereas
overexpression of Pten upon infection with a vector encoding
human Pten (Pten-OE [Furnari et al., 1997]) enhanced AICD in
WEHI cells upon anti-IgM treatment (Figures 5E and 6G). Further
experiments using a PI3K inhibitor in control CD19wt cells reca-
pitulated the increased AICD and the impaired Akt/GSK3/c-Myc
activation (Figure S4) observed in CD19kd cells. In addition, we
found that knockdown of CD19 in AICD-resistant human and
mouse cells suppressed PI3K activity and conferred significant
sensitivity to AICD (Figure S5). From this, we concluded that
knockdown of CD19 suppresses PI3K due to a reduced activity
of the c-Myc/miR17-92/Pten axis, which leads to increased
expression of Pten and results in increased sensitivity to AICD,
a process reversible by altering the activity of the c-Myc/
miR17-92/Pten axis.
To further confirm these findings, we performed the recip-
rocal experiment where we transfected WEHI-231 cells with hu-
man CD19 (hCD19) to overexpress functional CD19 in theseCell Reports 16, 419–431, July 12, 2016 423
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Figure 4. Partial Rescue of CD19KO B Cells by miR17-92 Overexpression
(A) Representative flow cytometry analysis of splenocytes from the indicated genotypes shows presence/absence of cell-surface CD19 expression on B220+
B cells. Numbers adjacent to outlined areas indicate percentage of cells among total splenocytes in each gate.
(B) Spleens of mice of the indicated genotypes; two spleens per genotype are shown.
(C) Representative flow cytometry analysis of splenocytes from the indicated genotypes shows percentage of cells among total splenocytes for transitional
B cells (B220+AA4.1+), mature B2 B cells (B220+AA4.1–), follicular (FO) B cells (B220+AA4.1–IgM+CD1dlow), and marginal zone (MZ) B cells (B220+AA4.1–
IgM+CD1dhigh).
(legend continued on next page)
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cells. Cells overexpressing CD19 that were sorted (Figure 5F)
exhibited augmented PI3K activity as revealed by increased
phosphorylation of Akt, GSK3, and consequential elevation
in expression of c-Myc (Figure S6). Further, we found in
hCD19+ cells increased expression of miR19b (Figure 5G)
and reduced expression of Pten mRNA and protein (Figures
5G and 5H), suggesting that the enhanced PI3K in hCD19+
cells may reflect the augmented activity of the c-Myc/miR17-
92/Pten axis. Upon ligation of the BCR, we found that over-
expression of CD19 and the consequential enhancement of
the PI3K pathway conferred partial resistance to AICD. Thus,
while 33% apoptosis were recorded in the control (hCD19–)
cells, the fraction of apoptotic cells overexpressing CD19
was reduced by 50% (Figure 5F). Taken together, these data
suggest that the c-Myc/miR17-92/Pten axis regulates the
sensitivity of B cells to AICD and that alteration of this axis,
such as by modification of CD19 expression, may affect cell-
fate decisions.
Altering Expression of miR17-92 Modifies PI3K Activity
and Sensitivity to AICD
To reveal the role of the c-Myc/miR17-92/Pten axis in con-
trolling PI3K-mediated AICD, wemodifiedmiR17-92 expression.
Ectopic overexpressionofmiR17-92 in theAICD-sensitiveWEHI-
231 cells suppressed Pten expression (Figure 6A) and led to
augmented PI3K activity (Figure 6B). This was also supported
by increased phosphorylation and inactivation of GSK3 and
elevation of c-Myc expression, which was sustained at high level
even after BCR ligation (Figure 6C). In agreement with an earlier
study (Kluiver and Chen, 2012), we show that upon ligation of
the BCR the augmented PI3K activity, which was obtained here
by overexpression of miR17-92, effectively conferred protection
from AICD as apoptosis rates were reduced by about 50%
(Figure 6D).
In a reciprocal experiment, we infected WEHI-231 cells
with the miR19b-sponge encoding vector (Kluiver et al., 2012)
to reduce expression of this miRNA. We found that expression
of Pten is increased in these cells (Figure 6E). Further, upon
BCR ligation we observed a significant increase in apoptosis
(Figure 6F). This increase, however, was blocked in cells co-
transfected with miR19b-sponge and shPten (Figures 6F and
6G), suggesting that the increased apoptosis induced by the
miR19b-sponge is mediated via the alteration of Pten expres-
sion. Taken together, these findings further support the major
role of the c-Myc/miR17-92/Pten axis in balancing PI3K activity
and setting the threshold for AICD in B lineage cells. Altering this
axis, such as by overexpression of miR17-92 or suppression of
miR19b, effectively confers Pten-mediated protection or sensi-
tivity, respectively, to AICD.(D) Graphs depict total cell numbers of the respective splenic subpopulations sh
(E) Representative flow cytometry analysis from the indicated genotypes show
(IgM+B220+/lowCD5+).
(F) Representative flow cytometry analysis from mice of the indicated genotypes
centage of cells among total splenocytes for germinal center (GC) B cells (B220+
(G) Graph depicts Serum IgG1 levels of the indicated genotypes on day 7 upon
All plots are gated on alive singlets. Graphs depict mean values and SDs of the re
test (*p < 0.05; **p < 0.01; ***p < 0.001).Overexpression of miR17-92 Protects Immature
CD19KO B Cells from AICD
Finally, to confirm the physiological relevance of the c-Myc/
miR17-92/Pten axis in controlling AICD, we stimulated immature
B cells from control, CD19KO, and CD19KO miR17-92Tg/Tg
mice that where grown in BM cultures with anti-BCR antibodies
and monitored apoptosis rates. Overexpression of miR17-92,
which restores the impaired PI3K activity in CD19KOB cells (Fig-
ures 3 and 4), protected immature B cells that are deficient of
CD19 from AICD (Figure 7). Thus, the heightened sensitivity to
BCR-mediated AICD that is evident in immature CD19KO B cells
(Figure 7, compared to control p < 0.05) was replaced by an
AICD-resistant phenotype, which we observed in cultures of
immature CD19KO miR17-92Tg/Tg B cells (p < 0.02, compared
to CD19KO).
DISCUSSION
Here, we show a regulatory loop by which the PI3K pathway
controls itself through post-transcriptional regulation of Pten in
normal B cell development. This loop connects a transcription
factor (c-Myc), amiRNA cluster (miR17-92) and a signalingmole-
cule (Pten) and functions by tuning PI3K activity to determine life
and death decisions in developing B cells during positive and
negative selection. Moreover, we show that miR17-92 over-
expression amplifies this axis to effectively compensate for the
impaired PI3K activity in CD19KO mice and to reconstitute
most of the B cell developmental impairments that are evident
in these mice. This provides evidence that miRNAs, by altering
intracellular biochemical pathways, are capable in restoring se-
vere developmental impairments that result from deficiency of
an important regulatory protein.
miR17-92 is essential for B cell development (Ventura et al.,
2008). We show here that miR17-92 participates in the Pten-
mediated regulation of the PI3K pathway, via the c-Myc/
miR17-92/Pten axis, to control positive and negative selection
of B lineage cells. This is evidenced by our findings that ablation
of Dicer in transitional B cells enhances Pten expression and
the observation that Pten expression level is inversely affected
by the level of PI3K activity upon suppression or overexpression
of CD19. Usingmultiple approaches, we show that the cross-talk
between the PI3K pathway and Pten is mediated via miR17-92.
The mechanism of this regulation is proposed in Figure 2A.
Accordingly, c-Myc, whose levels are regulated by PI3K activity
(Sears, 2004), stimulates miR17-92 expression, which promotes
degradation of Pten mRNA to dampen Pten protein levels. Most
importantly, our results validate the physiological relevance of
this major axis in vivo. In CD19KO miR17-92Tg/Tg mice, PI3K
activity is likely increased as a consequence of Pten suppressionown in (C) as well as total splenocyte numbers (n = 4–7).
s percentage of cells among peritoneal cavity derived cells for B1a B cells
on day 7 upon immunization with sheep red blood cells (SRBCs) shows per-
CD38lowFashigh) and class switched IgG1+ B cells (B220+CD38lowIgG1+).
immunization with SRBC (n = 3).
spective populations. Significance was calculated by the two-tailed Student’s t
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Figure 5. Modification of CD19 Expression Alters c-Myc/miR17-92/Pten Axis Activity and the Consequential Sensitivity to AICD
(A) BM cultures fromWT and CD19KOmice were grown for 5 days in the presence of IL-7. Immature B cells (B220+IgM+) were sorted and cultured in the presence
or absence of anti-IgM antibodies for 16 hr, and apoptosis rates were determined by PI stain. Shown are representative results from individual mice and summary
of group results (n = 3 in each group) expressed as mean ± SE (*p < 0.05).
(B and C) CD19wt and CD19kd WEHI 231 cells were lysed and analyzed by qPCR for Pten mRNA and mature miR19b (B) and for Pten protein expression by
western blotting (C). Results shown are mean ± SE of three experiments.
(D) CD19wt and CD19kd WEHI 231 cells were treated for 16 hr with anti-IgM antibodies in the presence or absence of the GSK3 inhibitor Bio-acetoxime and
analyzed for apoptosis by PI stain. Results are representative of three experiments.
(legend continued on next page)
426 Cell Reports 16, 419–431, July 12, 2016
A B C
D
E
F G
Figure 6. Modification of miR17-92 Expression Alters c-Myc/miR17-92/Pten Axis Activity and the Consequential Sensitivity to AICD
(A–D) WEHI-231 cells were infected with a viral vector to ectopically overexpress miR17-92. Control and ectopic miR17-92 WEHI 231 cells were lysed, and
expression of Pten protein was determined by western blotting (A), or the cells were stimulated with anti-IgM antibodies for the indicated time intervals lysed and
analyzed for pAkt (B, black line indicates assembly of different lanes from same blot) or the indicated proteins by western blotting (C), or the cells were stimulated
with anti-IgM antibodies for 16 hr and analyzed for apoptosis by PI stain (D).
(E and F) WEHI-231 cells were infected with a viral vector encoding a sponge system to miR19b. Control and miR19b sponge WEHI-231 cells were lysed to
determine Pten protein expression bywestern blotting (E), or the cells were stimulated with anti-IgM antibodies for 16 hr and analyzed for apoptosis by PI stain (F).
(G) Summary of PI results of WEHI cells infected with the indicated constructs upon anti-IgM stimulation. Shown are mean results from three to four repeats ±SE.
Significance shown is *p < 0.001; **p < 0.05 as calculated by Wilcoxon rank-sum test.(Figure 3), andmost of the B cell developmental impairments that
are evident in CD19KO mice are rescued (Figure 4). The finding
that this rescue depends on miR17-92 dosage (Figure 4D) sup-
ports the physiological relevance of this regulation and signifies
this finding. There are several other studies generally supporting
the relevance of this axis in regulating PI3K activity in B cells. (1)
Conditional overexpression of miR17-92 suppresses Pten and
leads to augmented PI3K signals and tumorigenesis (Jin et al.,
2013; Xiao et al., 2008). (2) In vivo ablation of Pten restores
B1a and MZ B cell development and activity in CD19/ mice
(Anzelon et al., 2003). (3) Constitutively active PI3K or Pten
deletion effectively enhance PI3K activity to rescue BCR-deleted(E) WEHI-231 cells were transfected with a shPten vector to knock down Pten e
Control and shPten cells were cultured for 12 hr with or without anti-IgM antib
co-treated for 12 hr with doxycycline (to induce Pten expression) and with or w
Summary of repeats and statistics are shown in Figure 6G.
(F–H) WEHI-231 cells were infected with a viral vector to overexpress hCD19 (S
hCD19 and sorted to hCD19– and hCD19+ as shown (F). Sorted cells were then tr
Shown are representative results from individual mice and summary of three expe
cells were lysed and analyzed by qPCR for PtenmRNA andmaturemiR19b (G) an
SE of three experiments.mature B cells in vivo (Srinivasan et al., 2009). While these
studies reveal the importance of tonic PI3K signals for normal
B cell development and survival, our findings uncover an
intracellular mechanism by which these tonic signals might be
balanced and the central role of miR17-92 in establishing it.
In striking contrast to the rescue of B1a and B2 cell develop-
ment, the MZ B cell population was not rescued in CD19KO
miR17-92Tg/Tg mice (Figure 4). TheMZ B cells comprise a small
subset of cells residing in the marginal zone of the spleen whose
development depends on BCR signal strength that is driven by
binding to self-antigen (Dammers and Kroese, 2005; Martin
and Kearney, 2002). Interestingly, and in contrast to our results,xpression, or with an inducible Tet-on vector to overexpress Pten (Pten-OE).
odies, and apoptosis rates were determined by PI stain. Pten-OE cells were
ithout anti-IgM antibodies, and apoptosis rates were determined by PI stain.
upplemental Experimental Procedures). Cells were stained with antibodies to
eated with anti-IgM antibodies for 16 hr and analyzed for apoptosis by PI stain.
riments expressed asmean ± SE (*p < 0.05) (F). hCD19+ and hCD19–WEHI 231
d for Pten protein expression by western blotting (H). Results shown aremean ±
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Figure 7. Overexpression of miR17-92 Protects CD19KO B Cells from AICD
(A and B) BM cultures frommice of the indicated genotypeswere prepared. Cells grown in cultures were stimulated with fluorescently labeled anti-IgM antibodies
for 16 hr, fixed, and stained for apoptosis by PI. Untreated cultures were stained after 16 hr for IgM, fixed, and stained for PI. Flow cytometry analysis for apoptosis
was performed and immature B cells were revealed by IgM fluorescence. Shown are representative results for PI analysis (A), and summary of results from
individual mice (n = 4–5 in each group) (B). Also shown are p values to indicate statistical differences in apoptosis increase in response to anti-IgM treatment
between groups as measured by Wilcoxon rank-sum test.in CD19KO PtenKO mice MZ B cells development is rescued
in addition to B1a and B2 cells (Anzelon et al., 2003). Yet, this
apparent contradiction could be explained by the differences
in levels of Pten expression. In the CD19KO miR17-92Tg/Tg
mice, Pten expression is reduced to a normal, or close to normal,
level (Figure 3), whereas in Anzelon et al. Pten is completely ab-
lated in B cells (Anzelon et al., 2003). Since Pten expression level
regulates PI3K activity (Suzuki et al., 2008), it is plausible that, in
the complete absence of Pten, PI3K activity is strong enough to
promote MZ cell differentiation. This notion is supported by the
finding that antigen-driven responsiveness of B2 cells was also
not reconstituted in CD19KO miR17-92Tg/Tg mice, as was
found in in CD19KO PtenKO mice (Anzelon et al., 2003).
Similar to MZ B cells, development of B1a cells is also regu-
lated by strength of BCR signaling, as low signal strength results
in a reduced B1a cell subset, whereas enhanced signaling ex-
pands this population (Berland and Wortis, 2002; Martin and
Kearney, 2001). The finding that B1a cell development is rescued
in CD19KO miR17-92Tg/Tg mice (Figure 4) suggests that over-
expression of miR17-92 reconstitutes PI3K activity in CD19KO
mice, via the c-Myc/miR17-92/Pten axis, to a level that is suffi-
cient to promote development of B1a cells. This is supported
by an earlier study showing that conditional deletion of Pten is
capable to reconstitute B1a cell development in mice deficient
of P110d catalytic subunit of PI3K (Janas et al., 2008).
In immature B cells undergoing central tolerance, strong BCR
signals activate AICD. Our data suggest that CD19 regulates the
signaling threshold for AICD in these cells by tuning PI3K activity428 Cell Reports 16, 419–431, July 12, 2016via the c-Myc/miR17-92/Pten axis. Thus, in the absence of CD19
PI3K is suppressed and immature B cells mount a heightened
sensitivity to AICD, whereas overexpression of CD19 enhances
PI3K activity and confers protection from AICD (Figure 5), sug-
gesting that CD19 may function as a molecular determinant for
cell-fate decision during negative selection. These observations
are in agreement with previous studies showing that chemical
inhibitors to PI3K enhance AICD in B lineage cells (Carey et al.,
2000), and that alterations in CD19 expression are associated
with autoimmunity in mouse and human (Inaoki et al., 1997; Saito
et al., 2002; Sato et al., 2000). CD19 expression and PI3K activity
have also been shown to be important for receptor editing
(Verkoczy et al., 2007) and anergy (Browne et al., 2009). Hence,
while in CD19KO mice peripheral B cell numbers are reduced
as a result of impaired maturation and differentiation (Diamant
et al., 2005; Engel et al., 1995; Otero and Rickert, 2003; Rickert
et al., 1995; Shivtiel et al., 2002), our findings suggest that
enhanced negative selection of immature/transitional B cells
by AICD may also contribute to this.
Furthermore, we demonstrate that, via this axis, PI3K controls
expression of Pten post-transcriptionally, and that Pten expres-
sion level pre-determines sensitivity to AICD. Thus, CD19KO
immature B cells mount heightened sensitivity to AICD, whereas
in CD19KO miR17-92Tg/Tg Pten expression is reduced to
normal level and immature B cells are protected from AICD (Fig-
ure 7). Clinically, it has been shown that expression level of
CD19 and enhanced PI3K activity contribute to the breakdown
of B cell tolerance and production of autoantibodies (Ball et al.,
2014; Sato et al., 2000), and PI3K inhibitors are now used as po-
tential therapeutic drugs for autoimmune diseases (Ball et al.,
2014). Our results suggest that some of the therapeutic activities
of these PI3K inhibitors might be mediated by the c-Myc/miR17-
92/Pten axis.
In this study, we used anti-IgM antibodies to mimic surrogate
self-antigen binding for negative selection by AICD, in both pri-
mary immature B cells and the WEHI-231 B cell line. It is impor-
tant to note that the capacity of anti-IgM to kill normal immature
B cells in vitro may not accurately reflect negative selection of
self-reactive B cells in vivo. Yet, this model for negative selection
of normal B cells has been shown to recapitulate self-tolerance
mechanisms that were studied in immunoglobulin-transgenic
mouse models with known self-specificity (Edry and Melamed,
2004; Monroe, 2006; Nemazee, 2000). Hence, BCR-mediated
PI3K activation by self-antigen or by anti-IgM may also function
in maintaining self-tolerance as we show here, in addition to its
other important roles at various stages of B cell development.
Clearly, Pten activity and Pten protein turnover are regulated
by additional mechanisms (Carracedo and Pandolfi, 2008; Papa-
konstanti et al., 2007; Xu et al., 2010), as well as at the transcrip-
tional level (reviewed in Carracedo and Pandolfi, 2008). Although
some or all of these mechanisms may apply to the regulation of
Pten in B lineage cells, we believe that c-Myc/miR17-92/Pten is
an axis shown to control its expression at the post-transcrip-
tional stage. It is worth noting that other microRNAs, such as
miR106 and miR181, were shown to regulate Pten and PI3K ac-
tivity in other cell lineages, but the mechanism regulating their
expression is unclear (Henao-Mejia et al., 2013).
Finally, in addition to positive and negative selection, CD19
expression and PI3K activity are important for B cell lymphoma
development and prognosis by enhancing expression of c-Myc
(Chung et al., 2012; Poe et al., 2012). Our results suggest that
in B cell lymphoma the c-Myc/miR17-92/Pten axis may function
as a vicious circle to suppress Pten expression and to maintain
enhanced PI3K activity. Indeed, evidence for the tumorigenic
function of this axis has been suggested by genomic screening
of Burkitt’s lymphoma cells (Schmitz et al., 2012). The fact that
Pten mutations and deletions are detected in many B cell neo-
plasms also supports this. Since PI3K inhibitors are now used
for treatment of B cell malignancies, it would be interesting to
study their effect on this axis. Our results suggest that inhibitors
for this axis may also be beneficial to treat cancer B cells.
EXPERIMENTAL PROCEDURES
Mice
CD19KO (homozygous for CD19-cre [Rickert et al., 1995]) and miR17-92Tg
mice (Xiao et al., 2008) have been described. All mice are C57BL/6 or have
been backcrossed to the C57BL/6 background for more than ten generations.
For the depletion-autoreconstitution model, we used mice transgenic for
human CD20 (hCD20Tg) (Ahuja et al., 2007). For in vivo Ablation of Dicer
and Pten, we used Dicerfl/fl (Murchison et al., 2005) and Ptenfl/fl (Trotman
et al., 2003) mice that were crossed with Mx-cre transgenic mice (K€uhn
et al., 1995), enabling ablating the floxed alleles upon in vivo administration
of poly(I)-poly(C). For T-dependent immunization experiments, mice were in-
jected once intravenously with 1 3 109 sheep red blood cells (SRBCs; Cedar-
lane). Mice were housed and bred at the animal facility of the Technion, Faculty
of Medicine (Israel) and the Max Delbr€uck Center for Molecular Medicine
(Berlin, Germany) and used for experiments at 7–12 weeks of age. Mousestudies at the Technion were approved by the local committee for the super-
vision of animal experiments. Animal care in Berlin followed guidelines of the
Max Delbr€uck Center for Molecular Medicine and the governmental review
board (Landesamt f€ur Gesundheit und Soziales Berlin, LaGeSo).
Cells and Stimulations
Splenic B cells were purified using a B cell isolation kit (STEMCELL Technolo-
gies), cultured in standard DMEM (supplemented with sodium pyruvate, Pen-
Strep antibiotics, and 2-mercapthoethanol), and treated as detailed. Cells
were lysed for western blotting analysis and for quantification of mRNAs and
microRNAs. WEHI-231 cells were cultured in standard DMEM. Cells were in-
fected with different viral vectors to knock down CD19, overexpress hCD19,
overexpress miR17-92 or to express a sponge system to miR-19b, overex-
press Pten, or knock down Pten. Stable transfectants were selected and
used for the experiments. Cells were lysed (see Methodology in the Supple-
mental Information) for western blotting and quantification of mRNAs and
miRNAs. BM cultures for B cell precursors were prepared as previously
described (Leider and Melamed, 2003). Cells grown in these primary cultures
(>95% B220+) were used as detailed.
Flow Cytometry
Single-cell suspensions from mouse organs were stained with fluorescently
labeled antibodies for surface and intracellular proteins to identify specific
B cell subsets, quantify level of expression and apoptosis and activation of
signaling pathways. Data were acquired on LSRFortessa (BD Pharmingen)
and analyzed using FlowJo software (Tree Star). For more details on cell prep-
arations antibodies and flourochromes, see Supplemental Experimental
Procedures.
ELISA
Immunoglobulin serum concentrations of SRBC immunized mice were deter-
mined as published (Roes and Rajewsky, 1993) (see details in Supplemental
Experimental Procedures).
Activation-Induced Cell Death
53 105WEHI-231 transfectants or 53 106 BM culture cells were cultured with
goat-anti-mouse IgM (10 mg/ml) (Southern Biotechnology Associates) or with
the F(ab’)2 of goat anti-mouse IgM or with Allophycocyanin (APC)-labeled
goat anti-mouse IgM (Jackson ImmunoResearch) for 12 hr to induce AICD.
Cells were collected, washed with PBS, and incubated for 10 min in dark
with propidium iodine (PI) solution (PBS containing 0.3% saponin, 5 mg/ml
propidium iodine, 50 mg/ml RNase, 5 mM EDTA [pH 8]). Apoptotic cells
were determined by their hypochromic sub-diploid staining profiles using
LSRFortessa, and the collected data were analyzed using FlowJo software.
Apoptotic rates for individual mice are expressed by fold increase calculated
as (anti-IgM-induced apoptosis – apoptosis in unstimulated)/apoptosis in un-
stimulated samples.
Statistical Analysis
The statistical significance of the differences between experimental groups
was determined using unpaired two-tailed Student’s t test with differences
considered significant at p < 0.05. In some experiments, statistical differences
in apoptosis increase between groups was measured using the Wilcoxon
rank-sum test using R software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.05.084.
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